北大医药董事长兼总裁徐晰人被刑拘

Core Viewpoint - North China Pharmaceutical (000788.SZ) is facing significant challenges, including a sharp decline in revenue and the recent detention of its chairman, which raises concerns about the company's future stability and management [1][3][4]. Financial Performance - For the first three quarters, the company reported revenue of 1.231 billion yuan, a year-on-year decrease of 19.76%, while net profit attributable to shareholders was 136 million yuan, an increase of 4.31% [1]. - In Q3 alone, revenue was 274 million yuan, down 47.95% year-on-year, and net profit was 35.6867 million yuan, a decline of 18.04% [1]. Management Issues - The chairman and president, Xu Xiren, was detained for criminal investigation, leading to a temporary delegation of his responsibilities to other executives [3]. - The company's stock price fell by 8.59% intraday, closing down 6.97% at 5.74 yuan per share, with a total market value of 3.421 billion yuan [3]. Control Changes - Xu Xiren became the actual controller of North China Pharmaceutical after acquiring a 22.22% stake through a series of transactions in December 2024 [3][4]. - The company has undergone significant management changes in the first half of the year, with multiple resignations from key positions [3][4]. Strategic Shift - North China Pharmaceutical is advancing its "de-Peking University" strategy, which involves severing ties with Peking University and changing its name [6][7]. - The company has announced plans to terminate its long-term service contract with Peking University International Hospital, which is expected to significantly impact revenue [6][7]. Revenue Impact - The company anticipates a revenue decrease of approximately 600 million yuan in 2025 and 1.027 billion yuan in 2026 due to the end of its collaboration with Peking University International Hospital [7].